1. Home
  2. PLRX vs PCRX Comparison

PLRX vs PCRX Comparison

Compare PLRX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.28

Market Cap

79.9M

Sector

Health Care

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$22.01

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLRX
PCRX
Founded
2015
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.9M
1.0B
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
PLRX
PCRX
Price
$1.28
$22.01
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
$2.67
$37.60
AVG Volume (30 Days)
533.4K
773.2K
Earning Date
03-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
29.97
107.44
EPS
N/A
0.16
Revenue
N/A
$541,533,000.00
Revenue This Year
N/A
$9.77
Revenue Next Year
N/A
$9.71
P/E Ratio
N/A
$141.53
Revenue Growth
N/A
26.04
52 Week Low
$1.09
$18.80
52 Week High
$1.95
$27.99

Technical Indicators

Market Signals
Indicator
PLRX
PCRX
Relative Strength Index (RSI) 49.99 46.76
Support Level $1.12 $20.09
Resistance Level $1.36 $23.82
Average True Range (ATR) 0.07 1.06
MACD -0.00 -0.09
Stochastic Oscillator 29.27 32.59

Price Performance

Historical Comparison
PLRX
PCRX

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: